{"hands_on_practices": [{"introduction": "A primary safety concern for any therapy derived from induced pluripotent stem cells (iPSCs) is the risk of teratoma formation from residual undifferentiated cells. To mitigate this risk, manufacturing processes must include rigorous purification steps and quality control assays. This exercise places you in the role of a translational scientist designing a release assay, demonstrating how fundamental probability is applied to determine the necessary sensitivity of a test to ensure a cell product is safe for clinical use [@problem_id:5070839].", "problem": "A translational medicine team is preparing a release assay for a clinical batch of induced pluripotent stem cell (iPSC)-derived dopaminergic progenitors intended for transplantation in Parkinson’s disease. To mitigate teratoma risk, the team needs to verify by flow cytometry that the frequency of residual undifferentiated cells is sufficiently low. Assume that each assayed cell constitutes an independent Bernoulli trial with probability $f$ of being an undifferentiated iPSC and probability $1-f$ of being a differentiated cell, and that the assay can reliably identify and gate undifferentiated cells without false positives or false negatives. The true residual fraction is estimated as $f = 0.001$ based on prior process characterization, and the lot will be rejected if the assay fails to detect any undifferentiated events in a sufficiently large sample because this would not provide enough confidence of detection.\n\nUsing only fundamental probability principles (independence, Bernoulli trials, the binomial model, and the complement rule), determine the smallest integer sample size $N$ (the number of flow cytometry events acquired) such that the probability of observing at least one undifferentiated iPSC in the sample is at least $0.95$. Provide your final answer as the minimal integer $N$ with no units. No rounding instruction is needed beyond identifying this smallest integer.", "solution": "The problem requires determining the minimum integer sample size, $N$, of cells to be assayed by flow cytometry to ensure that the probability of detecting at least one undifferentiated induced pluripotent stem cell (iPSC) is at least $0.95$.\n\nLet $X$ be the random variable representing the number of undifferentiated iPSCs observed in a sample of $N$ cells. The problem states that each cell constitutes an independent Bernoulli trial. The probability of success (observing an undifferentiated iPSC) is given as $f = 0.001$. The probability of failure (observing a differentiated cell) is $1-f = 1 - 0.001 = 0.999$.\n\nSince we have a fixed number of independent Bernoulli trials ($N$) with a constant probability of success ($f$), the random variable $X$ follows a binomial distribution, denoted as $X \\sim B(N, f)$. The probability mass function (PMF) for a binomial distribution is given by:\n$$P(X=k) = \\binom{N}{k} f^k (1-f)^{N-k}$$\nwhere $k$ is the number of successes, which can range from $0$ to $N$.\n\nThe objective is to find the smallest integer $N$ that satisfies the condition that the probability of observing at least one undifferentiated iPSC is at least $0.95$. Mathematically, this is expressed as:\n$$P(X \\ge 1) \\ge 0.95$$\n\nDirectly calculating this probability would involve summing the probabilities for $k=1, 2, ..., N$:\n$$P(X \\ge 1) = \\sum_{k=1}^{N} \\binom{N}{k} f^k (1-f)^{N-k}$$\nThis summation is cumbersome. It is more efficient to use the complement rule. The complement of the event \"at least one undifferentiated iPSC is observed\" ($X \\ge 1$) is the event \"zero undifferentiated iPSCs are observed\" ($X=0$). The sum of the probabilities of an event and its complement is $1$.\n$$P(X \\ge 1) = 1 - P(X=0)$$\n\nSubstituting this into our inequality gives:\n$$1 - P(X=0) \\ge 0.95$$\nRearranging the inequality to solve for $P(X=0)$:\n$$P(X=0) \\le 1 - 0.95$$\n$$P(X=0) \\le 0.05$$\n\nNow, we calculate $P(X=0)$ using the binomial PMF with $k=0$:\n$$P(X=0) = \\binom{N}{0} f^0 (1-f)^{N-0}$$\nBy definition, $\\binom{N}{0} = 1$ and for any non-zero $f$, $f^0 = 1$. Therefore, the expression simplifies to:\n$$P(X=0) = (1-f)^N$$\n\nSubstituting this back into our inequality, we get:\n$$(1-f)^N \\le 0.05$$\nWe are given $f=0.001$. So, the inequality becomes:\n$$(1 - 0.001)^N \\le 0.05$$\n$$(0.999)^N \\le 0.05$$\n\nTo solve for $N$, we take the natural logarithm ($\\ln$) of both sides.\n$$\\ln\\left((0.999)^N\\right) \\le \\ln(0.05)$$\nUsing the logarithm property $\\ln(a^b) = b \\ln(a)$, we have:\n$$N \\ln(0.999) \\le \\ln(0.05)$$\n\nIt is critical to note that for any argument less than $1$, the natural logarithm is negative. Specifically, $\\ln(0.999) < 0$. Therefore, when we divide both sides of the inequality by $\\ln(0.999)$, we must reverse the direction of the inequality sign:\n$$N \\ge \\frac{\\ln(0.05)}{\\ln(0.999)}$$\n\nNow we can evaluate the right-hand side.\n$$N \\ge \\frac{-2.99573227355...}{-0.00100050033...}$$\n$$N \\ge 2994.2307...$$\n\nSince the sample size $N$ must be an integer, we must select the smallest integer that satisfies this condition. The smallest integer greater than or equal to $2994.2307...$ is $2995$.\n\nThus, the smallest integer sample size required to ensure at least a $0.95$ probability of detecting at least one undifferentiated iPSC is $2995$.", "answer": "$$\\boxed{2995}$$", "id": "5070839"}, {"introduction": "The ultimate goal of many iPSC-based therapies is to create \"off-the-shelf\" products that can treat large numbers of patients. This allogeneic approach, however, faces the significant hurdle of immune rejection, which is primarily governed by the Human Leukocyte Antigen (HLA) system. This problem explores a leading strategy to overcome this barrier: the creation of a bank of iPSC lines from donors who are homozygous for common HLA haplotypes. By applying principles of population genetics, you will quantify the potential coverage of such a bank, providing a crucial assessment of its feasibility and utility for serving a diverse patient population [@problem_id:5070831].", "problem": "A national translational medicine program is designing an induced pluripotent stem cell (iPSC) bank comprised of Human Leukocyte Antigen (HLA)-homozygous lines to enable allogeneic therapies with minimized immunological risk. Each iPSC line is homozygous for a three-locus HLA haplotype spanning HLA-A, HLA-B, and HLA-DR. Let the selected bank lines correspond to haplotypes $\\{h_1,h_2,h_3,h_4,h_5,h_6,h_7\\}$, each denoting an exact allele-level match across HLA-A, HLA-B, and HLA-DR.\n\nThe country’s recipient population is modeled as an admixed mixture of three subpopulations: Group $\\mathrm{EA}$, Group $\\mathrm{EU}$, and Group $\\mathrm{AF}$, with mixture weights $w_{\\mathrm{EA}}=0.4$, $w_{\\mathrm{EU}}=0.4$, and $w_{\\mathrm{AF}}=0.2$. Within each subpopulation, the three-locus haplotype frequencies for the selected bank haplotypes are as follows:\n- Group $\\mathrm{EA}$: $f_{\\mathrm{EA},1}=0.12$, $f_{\\mathrm{EA},2}=0.10$, $f_{\\mathrm{EA},3}=0.09$, $f_{\\mathrm{EA},4}=0.08$, $f_{\\mathrm{EA},5}=0.06$, $f_{\\mathrm{EA},6}=0.05$, $f_{\\mathrm{EA},7}=0.04$.\n- Group $\\mathrm{EU}$: $f_{\\mathrm{EU},1}=0.09$, $f_{\\mathrm{EU},2}=0.07$, $f_{\\mathrm{EU},3}=0.05$, $f_{\\mathrm{EU},4}=0.04$, $f_{\\mathrm{EU},5}=0.03$, $f_{\\mathrm{EU},6}=0.02$, $f_{\\mathrm{EU},7}=0.01$.\n- Group $\\mathrm{AF}$: $f_{\\mathrm{AF},1}=0.05$, $f_{\\mathrm{AF},2}=0.04$, $f_{\\mathrm{AF},3}=0.03$, $f_{\\mathrm{AF},4}=0.03$, $f_{\\mathrm{AF},5}=0.02$, $f_{\\mathrm{AF},6}=0.02$, $f_{\\mathrm{AF},7}=0.01$.\n\nAssume: (i) recipients are diploid and each individual’s two three-locus HLA haplotypes are sampled according to the given subpopulation-specific haplotype frequencies; (ii) Hardy–Weinberg equilibrium and random mating hold within each subpopulation; (iii) phase is known and recombination within the three-locus haplotype is negligible for the purpose of this coverage estimate; (iv) a potential recipient is considered matched if at least one of their two three-locus haplotypes is an exact match to one of the bank’s selected haplotypes; and (v) the overall population coverage is computed by weighting each subpopulation’s coverage by its mixture weight.\n\nUsing only these assumptions and the data above, compute the overall population coverage of this HLA-homozygous iPSC bank, expressed as a decimal fraction. Round your final answer to four significant figures. No units are required.", "solution": "The objective is to compute the overall population coverage, $C_{\\text{total}}$, of the specified HLA-homozygous iPSC bank. According to assumption (v), this is the weighted average of the coverage in each subpopulation. Let $C_{\\mathrm{EA}}$, $C_{\\mathrm{EU}}$, and $C_{\\mathrm{AF}}$ be the coverage for Group $\\mathrm{EA}$, Group $\\mathrm{EU}$, and Group $\\mathrm{AF}$, respectively. The overall coverage is then:\n$$C_{\\text{total}} = w_{\\mathrm{EA}} C_{\\mathrm{EA}} + w_{\\mathrm{EU}} C_{\\mathrm{EU}} + w_{\\mathrm{AF}} C_{\\mathrm{AF}}$$\nWe must first compute the coverage for each subpopulation.\n\nLet us consider a generic subpopulation $k$, where $k \\in \\{\\mathrm{EA}, \\mathrm{EU}, \\mathrm{AF}\\}$. The coverage $C_k$ is defined as the probability that a randomly chosen individual from subpopulation $k$ is matched by the bank. A match occurs if at least one of the individual's two HLA haplotypes matches one of the $7$ haplotypes in the bank's collection.\n\nIt is more direct to first calculate the probability of the complementary event: an individual is *not* matched. An individual is not matched if and only if *neither* of their two haplotypes is present in the bank's collection.\n\nLet $H_B = \\{h_1, h_2, \\dots, h_7\\}$ be the set of bank haplotypes. For subpopulation $k$, let $F_k$ be the total frequency of these bank haplotypes. This is the sum of the individual haplotype frequencies:\n$$F_k = \\sum_{i=1}^{7} f_{k,i}$$\nThe probability that a single haplotype, drawn at random from the gene pool of subpopulation $k$, is one of the bank haplotypes is $F_k$. Consequently, the probability that a randomly drawn haplotype is *not* a bank haplotype is $1 - F_k$.\n\nAccording to assumption (ii), Hardy-Weinberg equilibrium holds within each subpopulation. This implies that the two haplotypes of a diploid individual are statistically independent samples from the subpopulation's haplotype pool. Therefore, the probability that an individual's first haplotype is not a bank haplotype AND their second haplotype is not a bank haplotype is the product of their individual probabilities:\n$$P(\\text{no match})_k = (1 - F_k) \\times (1 - F_k) = (1 - F_k)^2$$\nThe coverage $C_k$, which is the probability of a match, is the complement of having no match:\n$$C_k = 1 - P(\\text{no match})_k = 1 - (1 - F_k)^2$$\n\nNow we apply this formula to each subpopulation.\n\nFor Group $\\mathrm{EA}$:\nThe total frequency of bank haplotypes is:\n$$F_{\\mathrm{EA}} = 0.12 + 0.10 + 0.09 + 0.08 + 0.06 + 0.05 + 0.04 = 0.54$$\nThe coverage for Group $\\mathrm{EA}$ is:\n$$C_{\\mathrm{EA}} = 1 - (1 - F_{\\mathrm{EA}})^2 = 1 - (1 - 0.54)^2 = 1 - (0.46)^2 = 1 - 0.2116 = 0.7884$$\n\nFor Group $\\mathrm{EU}$:\nThe total frequency of bank haplotypes is:\n$$F_{\\mathrm{EU}} = 0.09 + 0.07 + 0.05 + 0.04 + 0.03 + 0.02 + 0.01 = 0.31$$\nThe coverage for Group $\\mathrm{EU}$ is:\n$$C_{\\mathrm{EU}} = 1 - (1 - F_{\\mathrm{EU}})^2 = 1 - (1 - 0.31)^2 = 1 - (0.69)^2 = 1 - 0.4761 = 0.5239$$\n\nFor Group $\\mathrm{AF}$:\nThe total frequency of bank haplotypes is:\n$$F_{\\mathrm{AF}} = 0.05 + 0.04 + 0.03 + 0.03 + 0.02 + 0.02 + 0.01 = 0.20$$\nThe coverage for Group $\\mathrm{AF}$ is:\n$$C_{\\mathrm{AF}} = 1 - (1 - F_{\\mathrm{AF}})^2 = 1 - (1 - 0.20)^2 = 1 - (0.80)^2 = 1 - 0.64 = 0.36$$\n\nFinally, we compute the overall population coverage $C_{\\text{total}}$ using the given mixture weights $w_{\\mathrm{EA}}=0.4$, $w_{\\mathrm{EU}}=0.4$, and $w_{\\mathrm{AF}}=0.2$:\n$$C_{\\text{total}} = w_{\\mathrm{EA}} C_{\\mathrm{EA}} + w_{\\mathrm{EU}} C_{\\mathrm{EU}} + w_{\\mathrm{AF}} C_{\\mathrm{AF}}$$\n$$C_{\\text{total}} = (0.4 \\times 0.7884) + (0.4 \\times 0.5239) + (0.2 \\times 0.36)$$\n$$C_{\\text{total}} = 0.31536 + 0.20956 + 0.072$$\n$$C_{\\text{total}} = 0.59692$$\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is $0.59692$. Rounding this to four significant figures gives $0.5969$.", "answer": "$$\\boxed{0.5969}$$", "id": "5070831"}, {"introduction": "For iPSC-derived therapies to be effective, the transplanted cells must not only be safe but also survive and function within the patient's body. When cells are delivered as a three-dimensional aggregate or spheroid, their survival is critically dependent on the diffusion of oxygen and nutrients from the surrounding tissue. This exercise delves into the fundamental principles of biotransport phenomena, asking you to model oxygen concentration within a spherical cell construct to determine the maximum size it can reach before its core becomes dangerously hypoxic. This calculation is vital for the rational design of engineered tissues and cell delivery vehicles that can ensure long-term therapeutic efficacy [@problem_id:5070838].", "problem": "A bioengineered implant consisting of Induced Pluripotent Stem Cells (iPSCs) is assembled as a compact, approximately spherical spheroid of radius $R$ embedded within a perfused hydrogel. Oxygen transport within the spheroid is governed by diffusion and cellular consumption. Assume the following scientifically grounded model: oxygen diffuses with coefficient $D$ (Fickian diffusion), the consumption rate per unit volume is approximately uniform and equal to $q$ (zero-order kinetics under near-normoxic conditions), and the external perfusion maintains an oxygen concentration $c_{0}$ at the spheroid surface. Let the system be at steady state, spherically symmetric, and let the onset of hypoxia in the core be defined by the central oxygen concentration reaching a threshold $c_{\\mathrm{hyp}}$.\n\nStarting from Fick’s first law and steady-state mass conservation, derive the oxygen concentration profile $c(r)$ inside the spheroid of radius $R$. From this profile, obtain an expression for the central concentration $c(0)$ and use it to define the critical spheroid radius $R_{\\mathrm{crit}}$ at which $c(0) = c_{\\mathrm{hyp}}$. Clearly state the assumptions used and show the dependency of $R_{\\mathrm{crit}}$ on the parameters $D$, $q$, $c_{0}$, and $c_{\\mathrm{hyp}}$. In the limit $c_{\\mathrm{hyp}} \\ll c_{0}$, simplify your expression to reveal the leading-order scaling of $R_{\\mathrm{crit}}$.\n\nFinally, compute $R_{\\mathrm{crit}}$ using the following physiologically plausible values measured for a dense iPSC-derived cardiomyocyte spheroid in a translational hydrogel scaffold under controlled perfusion: $D = 2.0 \\times 10^{-9}$ m$^{2}$ s$^{-1}$, $q = 2.0 \\times 10^{-2}$ mol m$^{-3}$ s$^{-1}$, $c_{0} = 6.0 \\times 10^{-2}$ mol m$^{-3}$, and $c_{\\mathrm{hyp}} = 5.0 \\times 10^{-3}$ mol m$^{-3}$. Express the final radius in micrometers and round your answer to $4$ significant figures.", "solution": "The derivation of the oxygen concentration profile, $c(r)$, and the critical spheroid radius, $R_{\\mathrm{crit}}$, proceeds as follows.\n\nThe problem is governed by the principle of mass conservation for the oxygen species within the spheroid. The general mass balance equation in a control volume is:\n$$ \\text{accumulation} = \\text{flux in} - \\text{flux out} + \\text{generation} $$\nIn differential form for a species with concentration $c$, this is expressed as:\n$$ \\frac{\\partial c}{\\partial t} = -\\nabla \\cdot \\vec{J} + S $$\nwhere $\\vec{J}$ is the molar flux vector and $S$ is the net rate of production per unit volume (a source or sink term).\n\nWe apply the assumptions given in the problem statement:\n1.  **Steady State**: The system does not change with time, so $\\frac{\\partial c}{\\partial t} = 0$.\n2.  **Spherical Symmetry**: The concentration $c$ is a function of the radial distance $r$ only, i.e., $c = c(r)$.\n3.  **Fickian Diffusion**: The mass flux is described by Fick's first law, $\\vec{J} = -D \\nabla c$, where $D$ is the constant diffusion coefficient. In spherically-symmetric coordinates, this reduces to a radial flux component $J_r = -D \\frac{dc}{dr}$.\n4.  **Zero-Order Consumption**: The oxygen is consumed at a constant, uniform rate $q$ per unit volume. This corresponds to a sink term, so $S = -q$.\n\nUnder spherical symmetry, the divergence of the flux vector is $\\nabla \\cdot \\vec{J} = \\frac{1}{r^2}\\frac{d}{dr}(r^2 J_r)$. Substituting these assumptions into the mass balance equation yields:\n$$ 0 = -\\frac{1}{r^2}\\frac{d}{dr}\\left(r^2 \\left(-D \\frac{dc}{dr}\\right)\\right) - q $$\nRearranging this gives the governing second-order ordinary differential equation (ODE) for the oxygen concentration profile $c(r)$:\n$$ \\frac{D}{r^2}\\frac{d}{dr}\\left(r^2 \\frac{dc}{dr}\\right) = q $$\nTo solve this ODE, we integrate it twice. First, we rearrange and integrate with respect to $r$:\n$$ \\frac{d}{dr}\\left(r^2 \\frac{dc}{dr}\\right) = \\frac{q}{D} r^2 $$\n$$ \\int \\frac{d}{dr}\\left(r^2 \\frac{dc}{dr}\\right) dr = \\int \\frac{q}{D} r^2 dr $$\n$$ r^2 \\frac{dc}{dr} = \\frac{q}{3D} r^3 + C_1 $$\nwhere $C_1$ is the first constant of integration. We can determine $C_1$ by applying a boundary condition. Due to the spherical symmetry of the problem, the concentration profile must be smooth and have a zero gradient at the center of the spheroid ($r=0$). A non-zero gradient would imply a flux source or sink at the origin, which is physically not present. Therefore, we must have $\\frac{dc}{dr}|_{r=0} = 0$. From the equation above, $\\frac{dc}{dr} = \\frac{q}{3D} r + \\frac{C_1}{r^2}$. For the gradient to be finite and zero at $r=0$, we must set $C_1=0$.\nThe equation for the concentration gradient simplifies to:\n$$ \\frac{dc}{dr} = \\frac{q}{3D} r $$\nIntegrating a second time gives the concentration profile $c(r)$:\n$$ \\int dc = \\int \\frac{q}{3D} r dr $$\n$$ c(r) = \\frac{q}{6D} r^2 + C_2 $$\nwhere $C_2$ is the second constant of integration. This constant is determined by the boundary condition at the spheroid surface. The problem states that the external perfusion maintains an oxygen concentration of $c_0$ at the surface, so $c(r=R) = c_0$.\n$$ c_0 = \\frac{q}{6D} R^2 + C_2 \\implies C_2 = c_0 - \\frac{q R^2}{6D} $$\nSubstituting $C_2$ back into the expression for $c(r)$, we obtain the oxygen concentration profile inside the spheroid:\n$$ c(r) = \\frac{q}{6D} r^2 + c_0 - \\frac{q R^2}{6D} $$\n$$ c(r) = c_0 - \\frac{q}{6D}(R^2 - r^2) $$\nThis expression is valid for $0 \\le r \\le R$. The profile is parabolic, with its minimum at the center.\n\nNext, we find the central concentration, $c(0)$, by setting $r=0$ in the profile equation:\n$$ c(0) = c_0 - \\frac{q R^2}{6D} $$\nThe critical spheroid radius, $R_{\\mathrm{crit}}$, is defined as the radius $R$ for which the central concentration reaches the hypoxic threshold, $c(0) = c_{\\mathrm{hyp}}$. Substituting these into the equation for the central concentration:\n$$ c_{\\mathrm{hyp}} = c_0 - \\frac{q R_{\\mathrm{crit}}^2}{6D} $$\nWe now solve for $R_{\\mathrm{crit}}$:\n$$ \\frac{q R_{\\mathrm{crit}}^2}{6D} = c_0 - c_{\\mathrm{hyp}} $$\n$$ R_{\\mathrm{crit}}^2 = \\frac{6D(c_0 - c_{\\mathrm{hyp}})}{q} $$\n$$ R_{\\mathrm{crit}} = \\sqrt{\\frac{6D(c_0 - c_{\\mathrm{hyp}})}{q}} $$\nThis expression shows the dependency of $R_{\\mathrm{crit}}$ on the parameters $D$, $q$, $c_0$, and $c_{\\mathrm{hyp}}$.\n\nIn the limit where the hypoxic concentration threshold is much smaller than the external concentration, $c_{\\mathrm{hyp}} \\ll c_0$, the difference $(c_0 - c_{\\mathrm{hyp}})$ can be approximated by $c_0$. The expression for the critical radius simplifies to:\n$$ R_{\\mathrm{crit}} \\approx \\sqrt{\\frac{6Dc_0}{q}} $$\nThis reveals the leading-order scaling of the critical radius with the system parameters.\n\nFinally, we compute the numerical value for $R_{\\mathrm{crit}}$ using the provided data:\n$D = 2.0 \\times 10^{-9}$ m$^{2}$ s$^{-1}$\n$q = 2.0 \\times 10^{-2}$ mol m$^{-3}$ s$^{-1}$\n$c_0 = 6.0 \\times 10^{-2}$ mol m$^{-3}$\n$c_{\\mathrm{hyp}} = 5.0 \\times 10^{-3}$ mol m$^{-3}$\n\nFirst, calculate the concentration difference:\n$$ c_0 - c_{\\mathrm{hyp}} = (6.0 \\times 10^{-2}) - (5.0 \\times 10^{-3}) = (6.0 \\times 10^{-2}) - (0.5 \\times 10^{-2}) = 5.5 \\times 10^{-2} \\text{ mol m}^{-3} $$\nNow substitute all values into the full expression for $R_{\\mathrm{crit}}$:\n$$ R_{\\mathrm{crit}} = \\sqrt{\\frac{6 \\times (2.0 \\times 10^{-9} \\text{ m}^2 \\text{s}^{-1}) \\times (5.5 \\times 10^{-2} \\text{ mol m}^{-3})}{2.0 \\times 10^{-2} \\text{ mol m}^{-3} \\text{s}^{-1}}} $$\n$$ R_{\\mathrm{crit}} = \\sqrt{\\frac{(1.2 \\times 10^{-8}) \\times (5.5 \\times 10^{-2})}{2.0 \\times 10^{-2}}} \\text{ m} $$\n$$ R_{\\mathrm{crit}} = \\sqrt{\\frac{6.6 \\times 10^{-10}}{2.0 \\times 10^{-2}}} \\text{ m} = \\sqrt{3.3 \\times 10^{-8}} \\text{ m} $$\n$$ R_{\\mathrm{crit}} \\approx 1.81659 \\times 10^{-4} \\text{ m} $$\nThe problem requires the answer in micrometers ($\\mu$m). Since $1$ m $= 10^6$ $\\mu$m:\n$$ R_{\\mathrm{crit}} \\approx (1.81659 \\times 10^{-4}) \\times 10^6 \\text{ } \\mu\\text{m} = 181.659 \\text{ } \\mu\\text{m} $$\nRounding to $4$ significant figures, we get:\n$$ R_{\\mathrm{crit}} \\approx 181.7 \\text{ } \\mu\\text{m} $$", "answer": "$$\\boxed{181.7}$$", "id": "5070838"}]}